KEFAMAST

DRY COW INTRAMAMMARY SUSPENSION

DATA SHEET



INDICATIONS FOR USE

For the treatment of sub clinical mastitis infection present at drying off and to assist in preventing new infections occurring during the dry period.

BENEFITS

- A dry cow therapy combining a cephalosporin and an aminoglycoside giving broad spectrum antimicrobial activity
- The combination of antimicrobials leads to a synergistic effect against bacteria
- Cefalexin is a broad spectrum, penicillinase-resistant beta-lactam antibiotic which has a bactericidal action
- The withdrawal period of 40 days plus 60 hours is beneficial to herds with shorter dry periods

LIST No	UNIT PACKAGE	CASE SIZE
1KEF002	120 syringes	1



See reverse for Administration & Dosage

Kefamast
DRY COW
INTRAMAMMARY SUSPENSION

ACTIVE SUBSTANCES
Intramammary suspension. Cefalexin 500 mg, Dihydrostreptomycin (as Dihydrostreptomycin Sulphate) 500 mg.
A 10 ml intramammary syringe containing 9 g of a smooth pale pink or pale-yellow sterile product.

TARGET SPECIES
Dry cows.

INDICATIONS FOR USE
For the treatment of sub clinical mastitis infection present at drying off and to assist in preventing new infections occurring during the dry period.

AMOUNTS TO BE ADMINISTERED AND ADMINISTRATION ROUTE
For intramammary use only.
The contents of one injector should be infused into the teat canal of each quarter immediately after the last milking of the lactation.
Before infusion, the teat should be thoroughly cleaned and disinfected. Care should be taken to avoid contamination of the injector nozzle after the protective cap has been removed.

WITHDRAWAL PERIOD(S)
Foodstuffs for human consumption must not be taken during the treatment period.
With cows milked twice daily, milk for human consumption may only be taken from 60 hours after calving (that is, from the fifth milking).
If calving occurs within 40 days of treatment, milk for human consumption may only be taken from 40 days plus 60 hours after treatment.
Animals for human consumption may only be slaughtered from 28 days after the last treatment.

CONTRAINDICATIONS
Do not use in animals with known hypersensitivity to the active ingredients. Do not use in lactating cows. Do not use within 40 days of the estimated calving date.

SPECIAL WARNINGS FOR EACH TARGET SPECIES
None.

SPECIAL PRECAUTION(S) FOR USE IN ANIMALS
Not intended for use within 40 days of the estimated calving date.

SPECIAL PRECAUTIONS TO BE TAKEN BY THE PERSON ADMINISTERING THE VETERINARY MEDICINAL PRODUCT TO ANIMALS
Operators should avoid contact with this preparation as occasional skin allergy may occur. Penicillins and cephalosporins may cause hypersensitivity following injection, inhalation, ingestion or skin contact. Hypersensitivity to penicillins may lead to cross reactions to cephalosporins and vice versa. Allergic reactions to these substances may occasionally be serious.
Do not handle this product if you know that you are sensitised, or if you have been advised not to work with such preparations. Handle this product with care to avoid exposure. If you develop symptoms such as skin rash following exposure, seek medical advice and show this warning to your doctor. Swelling of the face, lips or eyes, or difficulty with breathing are more serious symptoms and require urgent medical attention.

ADVERSE REACTIONS
None known.

USE DURING PREGNANCY OR LACTATION
This product may be used in pregnant cattle. This product is contra-indicated for use in lactating cows.

INTERACTION WITH OTHER MEDICINAL PRODUCTS AND OTHER FORMS OF INTERACTIONS
None known.

OVERDOSE
Not applicable.

PHARMACODYNAMIC PROPERTIES
Pharmacotherapeutic Group: Cefalexin; combinations with other antibacterials. Cefalexin is a broad spectrum, penicillinase-resistant beta-lactam antibiotic. It exerts bactericidal action by inhibiting cell wall synthesis.
Dihydrostreptomycin is an aminoglycoside antibiotic. The drug binds to receptors on the 30S subunit of the ribosome where it induces misreading of the genetic code and consequently causes fatal inhibition of ribosomal protein synthesis in the bacteria. Aminoglycosides have a synergistic effect with becta-lactam antibiotics.

PHARMACOKINETIC PARTICULARS
Cefalexin has a half-life of about 1 hour and is excreted through the kidneys in the urine.
The half-life of dihydrostreptomycin is 1-2 hours. It is eliminated entirely by glomerular filtration.

MAJOR INCOMPATIBILITIES
None known.

SHELF-LIFE
Shelf-life of the veterinary medicinal product as packaged for sale: 12 months.

SPECIAL PRECAUTIONS FOR STORAGE
Do not store above 25°C.

NATURE AND COMPOSITION OF IMMEDIATE PACKAGING
A sterile intramammary injection provided in 10 ml white low density polyethylene syringe for single use only.

SPECIAL PRECAUTIONS FOR THE DISPOSAL OF UNUSED VETERINARY MEDICINAL PRODUCTS
Unused product or waste material should be disposed of in accordance with current practice for pharmaceutical waste under national waste disposal regulations.

MARKETING AUTHORISATION HOLDER
Bimeda Animal Health Limited
2, 3 & 4 Airton Close, Airton Road
Tallaght, Dublin 24
Ireland

MARKETING AUTHORISATION NUMBER
VPA 22033/041/001

LEGAL CATEGORY
POM

TAKE TIME  OBSERVE LABEL DIRECTIONS

www.bimeda.ie

Bimeda data sheet created: November 2021